Dr Khan is an Assistant Professor at the College of Health and Life Sciences at Hamad Bin Khalifa University. Dr. Khan completed his Master's in Molecular Cell Biology from Uppsala University, and then a PhD in the lab of Prof. Martin Bergo, a protein lipidation expert. In Bergo's lab, he identified the biochemical importance of the protein lipidation enzyme GGTase-I in immune cell function. He refuted the popular idea that GGTase-I can be a therapeutic target against inflammatory conditions. 

After finishing his PhD, he moved to The Francis Crick Institute (London) in Dr. Axel Behrens's Lab, where he worked on identifying the posttranslational regulators of a tumor suppressor protein FBW7 and mechanisms of chemotherapy resistance in cancer. Dr Khan’s postdoc work highlighted the importance of protein ubiquitylation and protein turnover in colorectal cancer. He found that FBW7 which is a tumor suppressor, is posttranslationally downregulated in several colorectal cancers. These findings challenge the popular belief that only somatic loss of function mutations can contribute to cancer development.

Dr Khan's lab now focusses on the posttranslational modifications like ubiquitylation and phosphorylation in colorectal cancer and cancer chemotherapy resistance. Findings from his lab has also embarked his team on identifying regulators of TGFb signaling in human cancers which is a major tumor suppressor pathway involved in cancer cell metastasis in later stages of cancer. His lab is funded by NPRP and Worldwide Cancer grants from Qatar national research fund and Worldwide Cancer Research respectively!